Thirty-four patients were included in a period from 1994 until 2013. Patients' charts were reviewed to obtain patients', treatment and tumor characteristics. DVH parameters were analyzed after reconstruction of the original brachytherapy plan plus delineation of intermediate risk CTV (CTVIR) and organs at risk. The target volume at time of BT was the GTVres and was defined by the treating doctor based on clinical examination and CT scan. The CTVIR was defined by the tumor extension at time of diagnosis. Survival rates were calculated using the Kaplan-Meier method. Morbidity was scored by CTCAE v3.0.
addition, coverage of the CTVIR was poor, which can however be explained by the fact that until recently our target at BT was exclusively based on GTVres. Finally, the use of MRI at time of BT seems necessary to better define the target.
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Cancer of uterine cervix: PET-CT, IMRT and HDR. M. Garcia-Aranda 1 , X. CHEN 
Material and Methods:
All patients with locally advanced cervical cancer (FIGO: IB 7 patients, II 10 patients, III 7 patients, IV 4 patients) treated with radical radiotherapy in our center from 2007 to October 2015 were reviewed. Twenty eight patients were treated with EBRT using intensity-modulated radiation therapy (IMRT) technique following by HDR brachytherapy +/-chemotherapy. Planification included CT (50%) or PET-CT (50%) for GTV delineation. The most common prescription was 50.4 Gy (1.8Gy per fraction) for pelvic lymph nodes +/-paraaortic lymph node with concomitant boost up to 60, 48 Gy (2,16Gy per fraction) for macroscopic nodal disease and parametrium affectation. HDR brachytherapy was applied using tandem (25 Gy in 5 fractions) in most patients. Toxicity was assessed according to RTOG-EORTC criteria. All statistical analysis was performed using SPSS vs 22.0.
Results: There was no grade 3 acute toxicity associated with EBRT. Only one case of grade 4 acute toxicity was observed after HDR gynecological brachytherapy. The median age was 51 years (range 39 -81). The median of follow up was 30 months (range 4 -85). The actuarial progression-free survival was 77% at 36 months. Median time to local progression has not been reached. The median overall survival was 30 (range 4-85) month.
Conclusion:
Radical radiotherapy +/-chemotherapy is still a standard treatment in locally advanced uterine cervical cancer with good local control and global survival. Dose escalation is possible using PET-CT and IMRT which allow better conformation and better tolerance. Results: With a median follow-up of 52 months (range, 13-71), the median rates of decline of PSA were -0.359, -0.199 and -0.127 ng/mL/month, respectively, for durations of 1, 2 and 3 years after radiotherapy, respectively. The decline of PSA was maximal in the first year and continuously decreased for durations of 2 and 3 year. The median PSA nadir was 0.27 ng/mL after a median 33 months. 5-year biochemical failure (BCF)-free survival was 100% for low-and intermediate-risk patients. Results: With a median follow-up of 53.6 months (range, 14-74), the median PSA nadir and median slope for SBRT were 0.23 ng/mL and -0.430, -0.199, -0.127 and -0.094 ng/mL/month, respectively, for durations of 1, 2, 3 and 4 years following radiotherapy. Similarly, for CF-EBRT, the median PSA nadir and median slopes were 0.37 ng/mL and -0.529, -0.138, -0.109 and -0.056 ng/mL/month, respectively. The slope of CF-EBRT was significantly different with a greater median rate of change for 1 year post radiotherapy than that of SBRT (p= 0.018). Contrastively, the slopes of SBRT for duration for 2, 3 and 4 year tended to be continuously greater than that of CF-EBRT (p=0.028, p=0.058 and p=0.128, respectively). The significantly lower PSA nadir was observed in SBRT (median nadir 0.23 ng/mL) compared with CF-EBRT (median nadir 0.37ng/mL) (p= 0.011). 5-year biochemical failure (BCF) free survival were 100% for SBRT and 80.8% for CF-EBRT (p=0.031).
EP-1332

Conclusion
